Therapeutic implications of advances in breast cancer biology;Implications thérapeutiques des progrès réalisé s dans la biologie du cancer du sein

Revue du Praticien

Volumn 54, Issue 8, 2004, Pages 865-870

  Bertucci, François ^a   Gonçalves, Anthony ^a   Maraninchi, Dominique ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; HORMONE RECEPTOR; MYC PROTEIN; UVOMORULIN;

BREAST CANCER; CANCER RISK; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC RISK; HUMAN; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RELIABILITY; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGY; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR BIOLOGY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; PHENOTYPE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 2542417920     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Lerebours F, Lidereau R. Molecular alterations in sporadic breast cancer. Crit Rev Oncol Hematol 2002; 44: 121-41.
2. Pritchard KI. Current and future directions in medical therapy for breast carcinoma: endocrine treatment. Cancer 2000; 88: 3065-72.
3. Stebbing J, Copson E, O'Reilly S. Herceptin (trastuzumab) in advanced breast cancer. Cancer Treat Rev 2000; 26: 287-90.
4. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-27.
5. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002; 29: 231-45.
6. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol 2002; 3: 137-44.
7. Janicke F, Prechtl A, Thomssen C et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.
8. The Chipping Forecast. Nat Genet 1999; 21 (Suppl.): 1-60.
9. Bertucci F, Nasser V, Granjeaud S et al. Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. Hum Mol Genet 2002; 11: 863-72.
10. van 't Veer LJ, Dai H, van De Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
11. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
12. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
13. Ahr A, Karn T, Solbach C et al, Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002; 359: 131-2.
14. Bertucci F, Viens P, Hingamp P et al. Breast cancer revisited using DNA array-based gene expression profiling. Int J Cancer 2003; 103: 565-71.